Equities

Hinova Pharmaceuticals Inc

688302:SHH

Hinova Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)28.32
  • Today's Change0.00 / 0.00%
  • Shares traded399.73k
  • 1 Year change-48.48%
  • Beta--
Data delayed at least 15 minutes, as of Jun 17 2024 08:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hinova Pharmaceuticals Inc is a Chinese company mainly engaged in the research and development of innovative drugs for critical illnesses. The Company focuses its research on the fields of tumor, metabolic diseases and other critical illnesses. The Company's research platforms include a deuterated drug development platform, a Proteolysis-targeting chimera (PROTAC) technology platform, a targeted drug discovery and validation platform, and a lead compound optimization screening platform. The Company has diversified product portfolios, which are in various clinical test phases, including HC-1119 for prostate cancer, HP501 for hyperuricemia, and HP558 for cancer of the esophagus, among others. The Company conducts clinical tests in domestic and overseas areas.

  • Revenue in CNY (TTM)0.00
  • Net income in CNY-266.00m
  • Incorporated2013
  • Employees179.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Chemclin Diagnostics Co Ltd455.80m150.93m2.69bn731.0017.801.94--5.900.37640.37641.143.450.26841.0217.03623,526.508.8911.019.8212.3274.7374.1933.1131.075.09--0.151836.64-4.284.00-3.44--44.10--
Shanghai MicuRx Pharmaceutical Co Ltd106.52m-467.10m2.72bn205.00--3.67--25.53-0.7129-0.71290.16261.130.08390.58025.74519,588.20-36.81---40.09--81.75---438.53--6.94--0.2497--88.31---91.16------
ChengDu Sheng Nuo Biotec Co Ltd457.56m72.78m2.80bn1.13k38.393.12--6.120.6510.6514.098.000.35050.94974.57405,639.805.577.477.009.4462.4670.5215.9015.821.2816.720.249521.839.939.379.0818.6954.71--
Hanshang Group Co Ltd1.36bn49.62m2.80bn2.38k55.661.63--2.050.17070.17074.655.840.37052.758.35573,421.201.162.001.923.8958.3557.243.134.890.33662.150.319815.030.18935.14-32.2425.6212.88--
Hinova Pharmaceuticals Inc0.00-266.00m2.80bn179.00--2.11-----2.69-2.690.0013.390.00105.68--0.00-17.03-31.86-18.39-37.18-------25,578.2411.83--0.0097---100.00--2.44--124.37--
Shanghai Aladdin Biochemical Tech Co Ltd414.81m85.68m2.81bn566.0028.132.66--6.770.36020.36021.383.800.28030.38989.21732,874.105.798.836.209.6160.0861.4920.6626.858.00--0.251945.716.5519.36-7.489.9531.41--
Hangzhou Biotest Biotech Co Ltd474.05m134.34m2.83bn629.0020.921.15--5.971.271.274.4823.080.17882.178.38753,658.605.0329.455.3233.3049.4056.8328.1341.5913.02--0.000929.32-76.7519.65-86.2241.3334.82--
Shanghai ZJ Bio-Tech Co Ltd241.21m-115.98m2.85bn305.00--0.7328--11.82-0.6425-0.64251.2619.980.05630.20571.59790,860.40-2.7117.08-2.8719.1867.5560.21-48.0834.1314.96--0.001634.15-88.214.10-118.00--35.93--
Shanghai Shenqi Pharmactcl Inv Mgt CoLtd2.33bn57.15m2.91bn1.43k49.281.29--1.250.11590.11594.374.420.72135.745.751,635,818.001.86-0.60022.33-0.741747.5956.642.57-0.91282.3412.170.104---2.004.7917.41-11.68-25.97--
Data as of Jun 17 2024. Currency figures normalised to Hinova Pharmaceuticals Inc's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

66.75%Per cent of shares held by top holders
HolderShares% Held
Penghua Fund Management Co., Ltd.as of 31 Dec 20234.63m20.45%
GF Fund Management Co., Ltd.as of 31 Dec 20233.95m17.46%
China Fund Management Co., Ltd.as of 31 Dec 20232.11m9.33%
China Universal Asset Management Co., Ltd.as of 31 Dec 20231.31m5.77%
Fullgoal Fund Management Co., Ltd.as of 31 Dec 20231.04m4.59%
Changsheng Fund Management Co., Ltd.as of 31 Dec 2023656.18k2.90%
Bosera Asset Management Co., Ltd.as of 31 Dec 2023514.40k2.27%
China Merchants Fund Management Co., Ltd.as of 31 Dec 2023320.70k1.42%
ABC-CA Fund Management Co., Ltd.as of 31 Dec 2023291.47k1.29%
Great Wall Fund Management Co., Ltd.as of 31 Dec 2023287.48k1.27%
More ▼
Data from 31 Dec 2023 - 13 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.